



Prior Authorization Approval Criteria

Coreg (carvedilol)

Generic name:	Carvedilol
Brand names:	Coreg, Coreg CR
Medication class:	Non-selective beta-blocker
FDA-approved uses:	Mild to severe heart failure, left ventricular dysfunction following myocardial infarction, hypertension
Available dosage forms:	Coreg: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg tablets Coreg CR: 10 mg, 20 mg, 40 mg, 80 mg capsules
Usual dose range:	Coreg: 3.125mg BID, may double dose every 2 weeks; max. 50 mg BID Coreg CR: 10 mg QD, may double dose every 2 weeks; max. 80mg QD
Approximate cost: (based on AWP 2007)	Coreg (all strengths): \$142.46 per month Coreg CR (all strengths): \$125.11 per month
Duration of therapy:	Indefinite.

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- Clinically documented mild to severe heart failure, left ventricular dysfunction following myocardial infarction, or hypertension
- Failed/intolerant to FCHP-preferred beta-blockers such as generic metoprolol or Toprol XL (metoprolol succinate)
-

Not approved if:

- Patient does not meet the above-stated criteria.
- Patient has any contraindications to carvedilol.

Step therapy requirements:

- Generic beta-blocker

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 11/15/04
Revised: 12/07/07